% Expired Patents = 50.0

EPO Patents = 1

Forward Citations = 40

Loading Chart...

2 inventors (with patents filed for the assignee):

Gary A Koppel (8 out of 50 patents)

Michael O Chaney (2 out of 3 patents)

8 patents: Sort by Forward Citations

1. 7998991 - Neurotherapeutic treatment for sexual dysfunction (2011-08-16),

2. 7842683 - Neurotherapeutic compositions and method (2010-11-30),

3. 7833998 - Oral neurotherapeutic cephalosporin sulfoxide and sulfone-containing compositions (2010-11-16),

4. 7166626 - Therapeutic treatment for sexual dysfunction (2007-01-23),

5. 6627625 - Treatment of behavioral disorders with &bgr;-lactam compounds (2003-09-30),

6. 6610681 - Neurotherapeutic clavulanate composition and method (2003-08-26),

7. 6489319 - Neurotherapeutic use of carboxypeptidase inhibitors (2002-12-03),

8. 6426342 - Use of &bgr;-lactamase inhibitors as neuroprotectants (2002-07-30),

Company Overview

Revaax Pharmaceuticals, LLC is a cutting-edge biopharmaceutical company focused on the development of innovative therapies for various diseases. Our mission is to improve the lives of patients through the discovery and commercialization of novel treatments. With a strong emphasis on research and development, we are dedicated to advancing healthcare through science and innovation.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

8 Patents

#109 in Indianapolis, IN

#495 in Indiana

#35,924 in US

Indianapolis, IN, United States of America

Revaax Pharmaceuticals, LLC

Forward Citations = 40

2 inventors:

Gary A Koppel (8 out of 50 patents)

Michael O Chaney (2 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Revaax Pharmaceuticals, LLC. Retrieved from https://idiyas.com/company/revaax-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

1 patent (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]